Enapotamab vedotin (ADC)

Catalog No.

DHD89599

Description

Enapotamab vedotin is an ADC consisting of an AXL-directed antibody and Monomethyl auristatin E (MMAE) used for the study of several solid tumors.

Species reactivity

Human

Clonality

Monoclonal

Target

AXL

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SEC.

Purification

Purified by Ion Exchange Chromatography.

Applications

Research Grade Biosimilar

Form

Liquid

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

HuMax-AXL-ADC

Clone ID

Enapotamab vedotin

Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma., PMID:35886842

Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade., PMID:33531370

Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer., PMID:31600169

Document Download

Enapotamab vedotin (ADC).pdf